scispace - formally typeset
J

Jack Cuzick

Researcher at Queen Mary University of London

Publications -  777
Citations -  87544

Jack Cuzick is an academic researcher from Queen Mary University of London. The author has contributed to research in topics: Breast cancer & Tamoxifen. The author has an hindex of 128, co-authored 754 publications receiving 79979 citations. Previous affiliations of Jack Cuzick include Lincoln's Inn & Kaiser Permanente.

Papers
More filters
Journal ArticleDOI

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

O. Abe, +412 more
- 14 May 2005 - 
TL;DR: The 10-year and 15-year effects of various systemic adjuvant therapies on breast cancer recurrence and survival are reported and it is found that the cumulative reduction in mortality is more than twice as big at 15 years as at 5 years after diagnosis.
Journal Article

Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.

C. Focan, +226 more
- 18 Sep 1998 - 
TL;DR: The age-specific benefits of polychemotherapy appeared to be largely irrespective of menopausal status at presentation, oestrogen receptor status of the primary tumour, and of whether adjuvant tamoxifen had been given.
Journal ArticleDOI

Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer

Eugenia E. Calle, +194 more
- 11 Oct 1997 - 
TL;DR: Of the many factors examined that might affect the relation between breast cancer risk and use of HRT, only a woman's weight and body-mass index had a material effect: the increase in the relative risk of breast cancer diagnosed in women using HRT and associated with long durations of use in current and recent users was greater for women of lower than of higher weight or body- mass index.
Journal ArticleDOI

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial.

TL;DR: Anastrozole is an effective and well tolerated endocrine option for the treatment of postmenopausal patients with hormone-sensitive early breast cancer and longer follow-up is required before a final benefit:risk assessment can be made.
Journal ArticleDOI

A wilcoxon-type test for trend

TL;DR: An extension of the Wilcoxon rank-sum test is developed to handle the situation in which a variable is measured for individuals in three or more groups and a non-parametric test for trend across these groups is desired.